Renal Cell Carcinoma Histology
Renal cell carcinoma comprises five major histologic subtypes—clear cell (70-85%), papillary (7-15%), chromophobe (5-10%), collecting duct (<1%), and translocation RCC—each with distinct microscopic features, molecular profiles, and clinical behaviors that directly impact treatment selection and prognosis. 1, 2
Major Histologic Subtypes and Microscopic Features
Clear Cell RCC (70-85% of cases)
- Microscopic hallmark: Cells with clear cytoplasm due to abundant glycogen and lipid accumulation, arranged in tubular and solid growth patterns with a prominent capillary stroma 1
- Molecular signature: VHL gene mutations with chromosomal loss at 3p25-26 in 34-56% of sporadic cases 1
- Immunohistochemistry: CD10-positive (86-94%), CAIX-positive (94%), CK7-negative or focal, vimentin-positive 2, 3
- Clinical behavior: Generally worse overall survival compared to chromophobe and papillary type I 2
- Multilocular cystic variant: Composed entirely of cysts lined by clear cells; represents a low-aggressivity variant 1
Papillary RCC (7-15% of cases)
- Microscopic hallmark: Malignant cells arranged around capillary cores (papillae) in 50-70% of the tumor 1
- Historical subtypes (no longer recommended): Type I with scarce cytoplasm (73% of cases) and Type II with eosinophilic cytoplasm (42% of cases); the 2022 WHO classification eliminated this subdivision due to poor inter-observer reproducibility 1, 2
- Molecular signature: Type I associated with c-MET mutations; Type II with fumarate-hydratase or SETD2 mutations 1, 2
- Immunohistochemistry: Strong α-methylacyl-CoA racemase expression; CD10-positive in 63-93% 1, 2, 3
- Clinical behavior: Type I has significantly lower risk of death than clear cell RCC; Type II has worse prognosis similar to clear cell 2
Chromophobe RCC (5-10% of cases)
- Microscopic hallmark: Polygonal cells with sharply defined cytoplasmic membranes (plant cell appearance); pale reticulated cytoplasm containing abundant 150-300 nm diameter invaginated vesicles 1
- Molecular signature: Chromosomal losses in 1,2,6,10,13,17, and 21; associated with Birt-Hogg-Dubé syndrome 1, 2
- Immunohistochemistry: Diffuse CK7-positivity (81.5%), c-kit (CD117) expression, CD10-negative, CAIX-negative 1, 2, 3
- Clinical behavior: More favorable prognosis than clear cell RCC 2
- Critical differential: Chromophobe RCC shows diffuse CK7 and c-kit positivity, whereas oncocytoma lacks these markers 3
Collecting Duct Carcinoma (<1% of cases)
- Microscopic hallmark: High nuclear grade cells with eosinophilic cytoplasm, predominant tubular arrangement, desmoplasia, and expression of high-molecular-weight cytokeratins 1
- Origin: Medullary distal nephron or Bellini ducts 1, 2
- Molecular signature: Chromosomal losses in 1q, 6p, 13q, 14,15, 21q, and 22 1
- Clinical behavior: Aggressive with poor prognosis 4
- Medullary RCC: Considered an undifferentiated variant of collecting duct carcinoma 1
Translocation RCC (Rare, primarily pediatric/young adults)
- Microscopic hallmark: Cannot be diagnosed by morphology alone; requires molecular confirmation 2, 5
- Molecular signature: Xp11.2-TFE3 gene fusion or t(6;11)(p21;q12)-TFEB fusion 1, 2
- Diagnostic requirement: Both immunohistochemistry and fluorescence in-situ hybridization (FISH) mandatory for patients ≤40 years with papillary or complex architecture 2, 3, 5
- Clinical behavior: Primarily affects children and young adults 1, 2
Molecular Pathways and Therapeutic Implications
Understanding the molecular pathway of each subtype is critical because it determines treatment response:
- Hypoxia-inducible pathway: Clear cell and papillary type II (via fumarate-hydratase gene) 1
- mTOR signaling pathway: Clear cell and papillary type II 1
- c-Met-RAF-MEK-ERK pathway: Papillary type I and translocation RCC 1
- c-kit-RAF-MEK-ERK pathway: Chromophobe 1
Grading and Prognostic Features
- ISUP nucleolar grading system (grades 1-4): Provides accurate prognostic information for clear cell and papillary RCC 2, 5
- Sarcomatoid or rhabdoid differentiation: Automatically defines grade 4 tumor regardless of underlying histology; paradoxically shows increased sensitivity to immune checkpoint inhibitors 2, 5, 6
- Required documentation: Necrosis, microscopic vascular invasion, and pTNM stage must be reported for all specimens 5
2022 WHO Classification Updates
The 2022 WHO classification introduced 11 molecular-defined RCC subgroups that cannot be diagnosed by morphology alone, requiring molecular testing (immunohistochemistry, FISH, or next-generation sequencing) for accurate classification. 2, 5
- FH-deficient RCC: Loss of fumarate hydratase expression; associated with hereditary leiomyomatosis-RCC syndrome; poor prognosis 3, 5
- SDH-deficient RCC: Loss of SDHB expression; requires dedicated molecular assays 3, 5
- ALK-rearranged RCC: Identification directs use of ALK-targeted inhibitors 5
Diagnostic Approach and Common Pitfalls
- Core needle biopsy: Provides histopathological confirmation with 86-100% sensitivity and 98-100% specificity; mandatory before ablative therapies and systemic treatment in metastatic disease 1, 5
- Never rely on imaging alone to determine RCC subtype; histopathology is required before systemic therapy 5
- Do not omit molecular testing in younger patients (<40 years) or difficult-to-classify tumors; use low threshold for hereditary syndrome markers (FH, 2-SC, SDHB) 3, 5
- Tumor seeding from biopsy is rare and should not preclude tissue diagnosis 5
- Do not use outdated Fuhrman grading; ISUP nucleolar grading is the current standard 5
Prognostic Genomics in Clear Cell RCC
- PBRM1 mutations: Associated with stage III features but generally favorable prognosis 2, 3, 5
- BAP1 mutations: Correlate with larger tumors, higher nuclear grade, and significantly worse cancer-specific survival 2, 3, 5
- SETD2 mutations: Implicated in tumor progression and increased aggressiveness 2, 3, 5
- MTOR mutations: Predict sensitivity to mTOR inhibitors (everolimus, temsirolimus) 5